Medscape

Long-Acting Risperidone Injection

Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...
Medscape

FDA OKs Once-Monthly Risperidone Injection for Schizophrenia

The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...
Monthly Prescribing Reference

Uzedy Approved for Maintenance Treatment of Bipolar I Disorder

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
WebMD

Uzedy: FDA Approves Once-a-Month Subcutaneous Injectable Risperidone for Bipolar I Disorder

What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...
Hosted on MSN

FDA Approves Risperidone Extended-Release Injectable Option for Bipolar 1 Disorder

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 disorder. For anyone managing bipolar 1 disorder, staying consistent with daily ...
Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Healio

Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of adverse events were similar in both dosing ...
Healio

FDA approves long-acting injection for schizophrenia

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...
Seeking Alpha

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

About Risperidone Extended-Release Injectable Suspension for Subcutaneous Use The extended-release subcutaneous risperidone injection is an investigational once-monthly or once-every-two-months ...